Edition:
United Kingdom

HBM Healthcare Investments AG (HBMN.S)

HBMN.S on Swiss Exchange

142.60CHF
17 Jan 2018
Change (% chg)

-- (--)
Prev Close
CHF142.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
8,718
52-wk High
CHF144.20
52-wk Low
CHF99.80

Chart for

About

HBM Healthcare Investments AG is a Switzerland-based venture capital company investing in emerging companies, mainly from the biotechnology and human medicine, diagnostics, as well as medical technology sectors. The Company focuses on unlisted companies, with two-thirds of assets being invested in private companies that offer... (more)

Overall

Beta: 0.49
Market Cap(Mil.): CHF838.46
Shares Outstanding(Mil.): 7.04
Dividend: 5.80
Yield (%): 4.87

Financials

  Industry Sector
P/E (TTM): -- 144.56 16.44
EPS (TTM): -- -- --
ROI: -- 6.02 10.61
ROE: -- 10.68 14.21

BRIEF-HBM Healthcare Investments Expects Profit Of Over CHF 85 Million For First 9 Months Of 2017/2018‍​

* FOR FIRST NINE MONTHS OF 2017/2018, EXPECTS A PROFIT OF OVER CHF 85 MILLION‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

03 Jan 2018

BRIEF-CSL And HBM Portfolio Company Vitaeris Announce Strategic Partnership

* CSL AND HBM PORTFOLIO COMPANY VITAERIS ANNOUNCE STRATEGIC PARTNERSHIP WITH OPTION TO ACQUIRE Source text - http://bit.ly/2jhdF6b Further company coverage: (Gdynia Newsroom)

05 Dec 2017

Novartis to buy French cancer specialist AAA for $3.9 billion

ZURICH Novartis has agreed to buy French-based Advanced Accelerator Applications (AAA) for $3.9 billion (2.99 billion pounds), giving it a platform in radiopharmaceuticals and access to a new therapy for the kind of cancer that killed Steve Jobs.

03 Nov 2017

Novartis to buy French cancer specialist AAA for $3.9 billion

ZURICH Novartis has agreed to buy French-based Advanced Accelerator Applications (AAA) for $3.9 billion (£2.95 billion), giving it a platform in radiopharmaceuticals and access to a new therapy for the kind of cancer that killed Steve Jobs.

30 Oct 2017

BRIEF-HBM Healthcare Investments invests $20 mln in Y-mAbs Therapeutics

* Y-MABS THERAPEUTICS CLOSES $50 MILLION FINANCING ROUND LED BY HBM HEALTHCARE INVESTMENTS‍​

24 Oct 2017

BRIEF-‍Y-mAbs Therapeutics raises $50 mln in equity financing

* Says closed a private placement among HBM Healthcare Investments and its current shareholders, raising $50 million​ Source text for Eikon:

24 Oct 2017

BRIEF-BaseHealth raises $8.5 mln in Series C funding

* BaseHealth - ‍overall investment of $8.5 million includes $2.5 million from lead investor HBM Healthcare Investments ​ Source text for Eikon: Further company coverage:

18 Oct 2017

BRIEF-HBM Healthcare Investments announces investment of $30 mln in Harmony Biosciences‍​

* ANNOUNCES INVESTMENT OF USD 30 MILLION IN HARMONY BIOSCIENCES‍​ Source text - http://bit.ly/2xXIxie Further company coverage: (Gdynia Newsroom)

06 Oct 2017

BRIEF-HBM Healthcare Investments completes ‍capital reduction ​

* ‍CAPITAL REDUCTION COMPLETED​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

14 Sep 2017

BRIEF-HBM Healthcare Investments Q1 loss at CHF 72 million

* Q1 LOSS 72 MILLION CHF Source text for Eikon: Further company coverage: (Gdynia Newsroom)

25 Jul 2017

Earnings vs. Estimates